FULL SUPPLEMENT: Real-World Cases Using Topical Clascoterone Cream in Acne

January 2025 | Volume 24 | Issue 1 | 733610s1 | Copyright © January 2025


Published online December 31, 2024

ET AL

Abstract
Acne vulgaris affects approximately 80% of young adults and adolescents in the world. Acne presents as comedones, pustules, papules, and nodules on the face, chest, shoulders, or back. It can lead to a significant decrease in quality of life with a high risk of associated depression and anxiety. Hyperstimulation of sebaceous glands by androgens play a pivotal role in acne pathogenesis. Clascoterone 1% cream is a first-in-class topical androgen receptor inhibitor approved for treatment of acne in patients 12 years and older. In the following real-world cases, expert dermatologists demonstrate use of clascoterone cream as monotherapy or in combination with other agents to treat acne in a variety of patients. Experts found that twice-daily use led to best overall results with patients.
In this supplement
 
Real-World Cases of Clascoterone Topical Treatment for Acne and Related Disorders
 
Acne vulgaris is a chronic, inflammatory disease of the pilosebaceous unit. The condition affects approximately 9% of the worldwide population with increased prevalence among young adults aged 12 to 24 years.Around 80% of young adults and adolescents are affected by acne with 15% to 20% of those cases being severe acne. Primary acne lesions are comedones (open or closed) and inflammatory lesions such as papules, pustules, and nodules.
 
Close Menu